
1 doi

2 Original research paper

3 **The *in-vitro* anticancer effects of FS48 from salivary glands of *Xenopsylla cheopis***
4 **on NCI-H460 cells via its blockage of voltage-gated K⁺ channels**

5 WEICHEN XIONG^{1,2,a},

6 HUIZHEN FAN^{1,a}

7 QINGYE ZENG²

8 ZHENHUI DENG²

9 GUANHUI LI²

10 WANCHENG LU²

11 BEI ZHANG²

12 SHIAN LAI³

13 XIN CHEN^{1,*}

14 XUEQING XU^{2,*}

15 ¹ *Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University,*
16 *Guangzhou 510282, China*

17 ² *Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences,*
18 *Southern Medical University, Guangzhou 510515, China*

19 ³ Department of Molecular Chemistry and Biochemistry, Faculty of Science and Engineering, Doshisha
20 University, Kyotanabe, Kyoto 610-0394, Japan

21 * Correspondence; e-mail: chen_xin1020@163.com; xu2003@smu.edu.cn

22 ^a These authors contribute equally to the work.

23 Accepted August 23, 2022

24 Published online August 23, 2022

25

26 ABSTRACT

27 Voltage-gated K⁺ (K_v) channels play a role in the cellular processes of various cancer cells, including
28 lung cancer cells. We previously identified and reported a salivary protein from the *Xenopsylla cheopis*,
29 FS48, which exhibited inhibitory activity against K_v1.1-1.3 channels when assayed in HEK 293T cells.
30 However, whether FS48 has an inhibitory effect on cancer cells expressing K_v channels is unclear. The
31 present study aims to reveal the effects of FS48 on the K_v channels and the NCI-H460 human lung cancer
32 cells through patch clamp, MTT, wound healing, transwell, gelatinase zymography, qRT-PCR and WB
33 assays. The results demonstrated that FS48 can be effective in suppressing the K_v currents, migration,
34 and invasion of NCI-H460 cells in a dose-dependent manner, despite the failure to inhibit the
35 proliferation. Moreover, the expression of K_v1.1 and K_v1.3 mRNA and protein were found to be
36 significantly reduced. Finally, FS48 decreases the mRNA level of MMP-9 while increasing TIMP-1
37 mRNA level. The present study highlights for the first time that blood-sucking arthropod saliva-derived
38 protein can inhibit the physiological activities of tumor cells via the K_v channels. Furthermore, FS48 can
39 be taken as a hit compound against the tumor cells expressing K_v channels.

40 *Keywords:* lung cancer; K_v channels; FS48; NCI-H460 cells; anticancer

41

42 As a type of ion channel commonly expressed in cells, voltage-gated K⁺ (K_v) channels play a critical
43 role in the process of cellular signal transmission for both excited cells and non-excited cells, like Ca²⁺
44 signal transmission, action potential repolarization, hormone secretion, and cell volume regulation (1–3).
45 Due to their significance to the above-mentioned physiological processes, K_v channels provide an ideal
46 target for the development of some new therapeutic drugs related to anti-cancer, autoimmune,
47 neurological, metabolic, and cardiovascular diseases.

48 Lung cancer is currently the malignant tumor with the highest morbidity and mortality around of
49 the world, non-small cell lung cancer (NSCLC) in particular has been the main cancer kind globally and
50 caused the death of more than 1.7 million annually (4, 5). The metastasis of lung carcinoma to important
51 organs like bone, brain, lung, and liver greatly contributes to the high cancer mortality and its crucial
52 steps include cell migration and invasion (6–9). Thus, their suppression is a matter of importance for the
53 treatment of NSCLC. Despite significant progress made in recent years regarding the targeted drugs
54 intended for the treatment of lung cancer, there are still no effective treatment drugs available for most
55 patients with advanced lung cancer, especially those with metastatic advanced lung cancer (10–13). More
56 and more studies have shown that ion channels are closely related to the proliferation, migration and
57 metastasis of cancer and have key roles in multiple signaling pathways (14). For example, voltage-gated
58 sodium channels (VGSCs) can enhance extracellular matrix (ECM) degradation and facilitate the
59 metastasis of various carcinomas (15–18). Meanwhile, the role of K_v channels in tumor proliferation and
60 growth has been demonstrated as applicable to a variety of cancer, including prostate cancer, colon cancer,
61 lung cancer, and breast cancer (19–23). Therefore, regulating the activity of ion channels is one of the

62 viable solutions to anti-cancer treatment.

63 To overcome the host's defense response and feed, blood-sucking arthropods usually secrete a rich
64 mixture of pharmacologically active proteins from the glands. So far, there have been hundreds of
65 different peptides and proteins responsible for regulating the hemostatic, immune, and inflammatory
66 response of host animals that have been identified and extracted from the salivary glands of blood-
67 sucking arthropods (24, 25). Some of them can produce significant anti-cancer effects, such as
68 suppressing the proliferation of tumor cells, inducing cell apoptosis, inhibiting angiogenesis, and
69 reducing the proliferation in endothelial cells (26). Especially, FS50, a Na_v1.5 channel blocking peptide
70 from salivary glands of *Xenopsylla cheopis* has been reported to inhibit the motility of MDA-MB-231
71 human breast cancer cells via suppressing Na_v1.5 channel (27). In previous studies, we identified a
72 potassium channel inhibitor, FS48, from the salivary gland of *X. cheopis*, which contains an atypical
73 dyad motif and can dose-dependently inhibit the K_v1.1-1.3 channels expressed in Raw 264.7, Jurkat T
74 and HEK 293T cells (28,29). K_v1.1 and K_v1.3 have been reported to be detected in HCl-H460 cells and
75 are considered potential therapeutic targets (23, 30). In this study, we confirm that FS48 can inhibit the
76 motility of NCI-H460 human lung cancer cells through the suppression of K_v currents and regulation of
77 MMP-9 and TIMP-1 expression.

78 EXPERIMENTAL

79 *Chemicals*

80 Fetal bovine serum (FBS), RPMI-1640 medium, phosphate-buffered saline (PBS),
81 streptomycin/penicillin, and 0.25 % trypsin-EDTA were purchased from Gibco (Waltham, MA, USA).
82 Human lung cancer cell line NCI-H460 was purchased from CTCC (Hangzhou China) and cultured at

83 37°C in a humidified 5 % CO₂ atmosphere in RPMI-1640 medium containing 10 % FBS and 1 %
84 streptomycin/penicillin. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and
85 dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (USA). Primary antibodies against
86 K_v1.1 and K_v1.3 were purchased from Alomone Labs (Israel), and β-actin was purchased from Abcam
87 (USA). TRIzol was purchased from Life Technologies (USA).

88 *Expression and purification FS48*

89 FS48 was expressed and purified as described in our previous studies and finally dissolved in water
90 and stored at -80 °C until use (28). SDS-PAGE analysis showed a protein purity greater than 95 %.

91 *Cell viability assay*

92 The effect of FS48 on NCI-H460 cells viability was determined by the MTT assay as reported in
93 our previous paper (31). Briefly, NCI-H460 cells (5×10^3 cells/well) were seeded into 96-well plates and
94 treated with 0, 2, 4, 8, or 16 μM of FS48 and incubated for 24, 48, and 72 h, respectively. Following
95 incubation, the cells were added with 10 μL MTT solution (5 mg mL⁻¹ in PBS) for another 4 h to form
96 formazan crystals in live cells. The formed formazan crystals were dissolved in DMSO, then the
97 absorbance was read at 570 nm by a microplate reader (Tecan, Switzerland). All experiments were
98 repeated three times.

99 *Cell migration assay*

100 The *in vitro* wound healing assay was performed to investigate the effect of FS48 on cell migration
101 activity. NCI-H460 cells were seeded at 5×10^5 cells per well into a 6-well plate and grown in serum-
102 free medium at 37 °C. Next day cell cultures were scratched using a P200 pipette tip. And then the
103 supernatant was removed, and the cells were washed with serum-free medium three times before were

104 incubated with $16 \mu\text{mol L}^{-1}$ FS48 for 24 and 48 h. Representative photographs were taken at 0, 24, and
105 48 h at the same position of each cell well by an inverted microscope (Zeiss, Germany), and the migration
106 index (MI) was calculated as $\text{MI} = 1 - (W_t/W_0) \times 100 \%$, where W_t is the width of the wounds at 24 or 48
107 h, W_0 is the width of the wounds at 0 h.

108 *Cell invasion assay*

109 Cell invasion was performed with a transwell chamber (Corning, USA) as previously described by
110 us (27). Briefly, 1×10^5 NCI-H460 cells were loaded into the upper chamber after incubation with 0, 2,
111 4, 8, and $16 \mu\text{mol L}^{-1}$ FS48 in RPMI-1640 medium without FBS for 1 h. And the lower chamber was
112 filled with RPMI-1640 medium contains 10 % FBS. Cells were allowed to migrate for 24 or 48 h at 37°C
113 before fixation. The top of the transwell was cleared of cells using a cotton swab. The cells move to the
114 lower chamber were stained with crystal violet, and photographed by an inverted microscope. The dye
115 was solubilized from the cells using 10 % (*V/V*) acetic acid, and the relative absorbance was quantified
116 using a multifunction microporous plate reader reading at 570 nm. The fraction of cell invasion inhibition
117 was calculated by normalizing to control cells. All experiments were repeated three times.

118 *Electrophysiological measurement*

119 Whole-cell K_v currents of NCI-H460 cells were measured using Sutter Patch Amplifier model IPA
120 (Sutter Instrument, USA) controlled by Igor 7 software (WaveMetrics, USA) (28). The external solution
121 contains (in mM): 5.9 KCl, 2.2 CaCl_2 , 137 NaCl, 10 HEPES, 1.2 MgCl_2 , and 14 D-glucose (adjusted to
122 pH 7.3 with KOH) and the pipette solution contains (in mmol L^{-1}): 140 KF, 4 MgCl_2 , 1 EGTA, 2 Na_2ATP ,
123 and 10 HEPES (adjusted to pH 7.3 with KOH). K_v currents were elicited by a 100 ms depolarization to
124 +25 mV from a holding potential of -70 mV. FS48 was dissolved in the external solution for the

125 electrophysiological experiments and was applied with an ALA VC3 perfusion system (ALA, USA). 20
126 mmol L⁻¹ TEA was used as a positive control. The data points were fitted to the Boltzmann equation:
127 $I/I_{\max} = 1/[1 + \exp(V - V_{1/2})/k]$ where k is the slope factor and $V_{1/2}$ is the voltage for half-maximum
128 activation.

129 *Gelatinase activity assay*

130 The modified gelatinase zymography assay was performed to analyze the activity of MMP-9
131 according to previous study (27). NCI-H460 cells were treated with 16 μmol L⁻¹ FS48 for 24 h. The
132 supernatant was collected and electrophoresed in a 10 % SDS-PAGE gel containing 0.1 % gelatin at 100
133 mV for 2 h in a non-reducing environment at 4 °C. MMP-9 was activated in gel for 16 h at 37 °C after
134 renatured with 2.5 % Triton X-100. Gels were then fixed, stained with 0.25 % Coomassie blue G-250
135 and destained. Gelatinase activity was quantified using Image Quant TL software (GE Healthcare, USA).
136 All experiments were repeated three times.

137
138 *Quantitative real-time PCR (qRT-PCR)*

139 NCI-H460 cells were seeded into the six-well plates and treated with 16 μmol L⁻¹ FS48 for 24 h.
140 Total RNA was isolated from the cultured cells with the TRIzol reagent, quantified using a Nanodrop
141 2000 instrument (Thermo Scientific, USA), and transcribed into cDNA using the iScript cDNA Synthesis
142 kit (Bio-Rad, USA) according to the manufacturer's instructions. qPCR was carried out with ABI 7500
143 Sequencing Detection System (Applied Biosystems, USA) and SYBR premix Ex Taq (Takara, Japan)
144 according to the manufacturer's instruction. The primer sequences used for qPCR were listed as follow:

145 GAPDH (forward: 5'-CGGAGTCAACGGATTTGGTCGTAT-3'; reverse: 5'-

146 AGCCTTCTCCATGGTGGTGAAGAC-3'); MMP-9 (forward: 5'-GACGAGGGCCTGGAGTGT-3';
147 reverse: 5'-TGTGCTGTAGGAAGCTCATCTC-3'); TIMP-1 (forward: 5'-ACCCCTGGAGCACGGCT-
148 3'; reverse: 5'-CCCACCTTCCAAGTTAGTGACA-3'); Kv1.1 (forward: 5'-
149 TGCAGTGTACTTTGCCGAGGCG-3'; reverse: 5'-GACACCACCGCCCACCAGAAAG-3'); Kv1.3
150 (forward: 5'-TGCGGTTCTTCGCTTGTC-3'; reverse: 5'-GTCCATTGCCCTGTCGTT-3'). Forty
151 amplification cycles were necessary to achieve exponential amplification. All experiments were repeated
152 three times. Products were quantified using $2^{-\Delta\Delta CT}$ method and Kv1.1, Kv1.3, MMP-9, and TIMP-1 gene
153 expression was normalized to the fold change of GAPDH mRNA.

154 *Western blot analysis*

155 5×10^5 NCI-H460 cells were maintained in a 6-well plate overnight and treated with 16 μ M FS48
156 for 24 h. The cells treated with PBS were considered as a negative control. Cells were harvested and
157 lysed with RIPA lysis buffer containing phosphatase and protease inhibitors (FDBio, China) on ice for 8
158 min and then centrifuged at 14,000 rpm at 4 °C for 15 min. The supernatant was prepared for western
159 blot analysis. Then, the denatured protein was loaded and separated using 10 % SDS-PAGE and
160 transferred onto PVDF membranes (Millipore, USA). Membranes were blocked with 5 % skim milk for
161 1 h at room temperature. Primary antibodies against Kv1.1 and β -Actin (4 °C, 16 h, 1:1000), and
162 horseradish peroxidase (HRP) conjugated secondary antibodies (26 °C, 2 h 1:1000) were used according
163 to the manufacturer's instructions, respectively. Finally, fluorescent signals were visualized and captured
164 with Kodak XAR film. All experiments were repeated three times.

165 *Statistical analysis*

166 All data are presented as mean \pm SEM. Data analysis used two-way analysis of variance (ANOVA)

167 followed by Tukey's multiple comparison tests. $p < 0.05$, $p < 0.01$, or $p < 0.001$ represented statistically
168 significant difference.

169

170

RESULTS AND DISCUSSION

171 *FS48 suppresses the motility but not proliferation of NCI-H460 cells*

172 The MTT assay showed that 2, 4, 8, and 16 $\mu\text{mol L}^{-1}$ of FS48 did not inhibit the proliferation of
173 NCI-H460 cells after incubation for 24, 48, and 72 h (Fig. 1a-c). In the wound healing assay, compared
174 with the control group, FS48 suppressed the migration of NCI-H460 cells at 16 $\mu\text{mol L}^{-1}$ after 24 and 48
175 h of treatment. In detail, untreated NCI-H460 cells accounted for about 37.3 and 52.2 % of the original
176 wound area after 24 and 48 h, respectively (Fig. 1d,e). However, after treated with 16 $\mu\text{mol L}^{-1}$ FS48 for
177 24 and 48 h, the cells only accounted for 9.86 and 18.20 % of the original wound area (Fig. 1e). We
178 further used the transwell invasion experiment to verify the inhibition of FS48 on NCI-H460 cells
179 migration. Consistent with the wound healing assay, all concentrations of FS48 (2, 4, 8, and 16 $\mu\text{mol L}^{-1}$)
180 significantly inhibited the number of NCI-H460 cells invading through the membrane pores, and the
181 inhibition was concentration-dependent (Fig. 1f,g).

182 *FS48 reduces K_v currents of NCI-H460 cells*

183 $K_v1.1$ and $K_v1.3$ channels are expressed in NCI-H460 cells (23). In addition, $K_v1.1$ channel has been
184 reported to play an important role in cell motility of NCI-H460 cells (30). It has been proven that FS48
185 can inhibit the $K_v1.3$ protein expression and activity in activated Raw 264.7 and Jurkat T cells after 24 h
186 incubation (28, 29). Therefore, the whole-cell patch clamp technique was performed to analyze the effect
187 of FS48 on K_v currents of NCI-H460 cells. K_v currents were elicited by applying 100 ms depolarization

188 to +25 mV from a holding potential of -70 mV. After the addition of 10 $\mu\text{mol L}^{-1}$ FS48, the peak K_v
189 currents in the NCI-H460 cells were reduced by about 49.56 % (Fig. 2a). A potent K_v blocker, TEA,
190 reduced K_v currents of NCI-H460 cells by 94.3 % at the concentration of 20 mmol L^{-1} (Fig. 2a). The
191 current-voltage relationships are presented in Fig. 2b. A significant decrease in current at all tested
192 voltages was observed in NCI-H460 cells by incubation with 10 $\mu\text{mol L}^{-1}$ FS48 or 20 mmol L^{-1} TEA.
193 Given the involvement of K_v channels in the modulation of several cells migration, blocking the K_v
194 channels can suppress cell migration, rather than cell proliferation, consistent with the results that FS48
195 inhibited NCI-H460 cells migration without affecting proliferation (32–35).

196 *FS48 inhibits the $K_v1.1$ and $K_v1.3$ expression in NCI-H460 cells*

197 Western blot experiment was performed to evaluate the effect of FS48 on $K_v1.1$ protein expression
198 in NCI-H460 cells. The $K_v1.1$ and $K_v1.3$ protein expression in NCI-H460 cells was reduced by 21.6 and
199 37.4 %, respectively after treated with 16 $\mu\text{mol L}^{-1}$ FS48 for 24 h in comparison with untreated cells (Fig.
200 3a,b). qRT-PCR experiment was furthered to determine the effect of FS48 on the $K_v1.1$ and $K_v1.3$ mRNA
201 level. Consistently, the $K_v1.1$ and $K_v1.3$ mRNA content in NCI-H460 cells decreased by 72.0 % and
202 66.0 % after treatment with FS48 for 24 h when compared with the control group (Fig. 3c). Together,
203 these results indicated that FS48 can play a significant role in suppressing K_v -dependent migration and
204 invasion for NCI-H460 cells by reducing the K_v current and $K_v1.1$ and $K_v1.3$ protein expression.

205 *FS48 decreases the mRNA levels of MMP-9 but increases TIMP-1 mRNA levels*

206 The migration and invasion of NSCLC are very important for its metastasis from the origin of
207 tumorigenesis to other body regions such as bone, brain, and spleen, which are greatly affected by matrix
208 metalloproteinases (MMPs) and their inhibitors which are essential in tissue remodeling and ECM

209 degradation. Thus, their suppression is indispensable for the treatment of NSCLC (4, 6). In the gelatinase
210 zymography assay, the activity of MMP-9 was significantly reduced by about 46.0 % in NCI-H460 cells
211 after treated with $16 \mu\text{mol L}^{-1}$ FS48 for 24 h when compared with the control group (Fig. 4a,b).
212 Consistently, $16 \mu\text{mol L}^{-1}$ FS48 significantly decreased the mRNA expression of MMP-9 but upregulated
213 TIMP-1, a natural inhibitor of MMPs, when compared with the control group in NCI-H460 cells (Fig.
214 4c). Thus, the reduced motility of NCI-H460 cells resulted from the decrease of MMP-9 and the increase
215 of TIPM-1 in FS48-treated cells. It is well known that modulation of MAPK/NF- κ B signaling pathways
216 are involved in the expression regulation of MMPs in NSCLC cells (36, 37). Our previous study showed
217 that FS48 can block K_v channels and subsequently inactivate the MAPK/NF- κ B pathways in activated
218 Raw 264.7 and Jurkat T cells (28, 29). Since FS48 can inhibit the K_v currents in NCI-H460 cells, it is
219 reasonable to assume that FS48 inhibits the mobility of NCI-H460 cells via its blockage of K_v channels
220 and the subsequently inactivation of the MAPK/NF- κ B pathways which finally regulate the expression
221 of MMP-9 and TIMP-1.

222 As one of the most effective treatment solutions to lung cancer currently, chemotherapy is frequently
223 combined with other drugs targeting different pathways in order to overcome their severe side effects
224 and drug resistance. $K_v1.1$ channel has been proven to be a potential target against various cancer and
225 address the resistance of tyrosine kinase inhibitors in NSCLC. FS48 has no impact on the proliferation
226 of NCI-H460 cells but inhibits the invasion and metastasis of the cells to a significant extent. Expsy
227 shows that as a protein with only 56 amino acids, FS48 has a small molecular weight (6 kD), a theoretical
228 isoelectric point of 8.83 and a grand average of hydropathicity (GRAVY) of -0.566 , indicating that it is
229 well soluble in water. The plasma half-life time of FS48 was about 353.1 min, which was significantly
230 better than that of MgTx, which is also a K_v channel inhibitor (29). The above results suggest that FS48

231 can be combined with other drugs such as small molecule antimetabolites, immunotherapy, endocrine
232 therapy, alkylating agents, and anti-mitotic inhibitors (38). Since these inhibitors have displayed
233 cytotoxic effects on lung cancer cells, it is theoretically viable for the combined treatment with FS48 to
234 produce better synergistic and therapeutic effects. Therefore, it is necessary to conduct further studies on
235 the combined effect of FS48 and other anti-cancer drugs to fully understand the role of FS48 in
236 combination therapy.

237 CONCLUSIONS

238 Our study shows that FS48 blocks functional K_v channels activity in the NCI-H460 cell model of
239 lung cancer by inhibiting the expression and activity of $K_v1.1$ and $K_v1.3$ channels and reducing cell
240 migration and invasion by reducing MMP-9 activity. Therefore, it is demonstrated in this study for the
241 first time that blood-sucking arthropod saliva-derived protein can play a role in inhibiting lung cancer
242 cell motility through blocking the K_v currents and channel protein expression. In addition, a new hit
243 molecule is identified in this study for the development of lung cancer metastasis drugs.

244 *Acknowledgments.* – The authors are very grateful for the financial support.

245 *Conflicts of interest.* – The authors declare no conflict of interest.

246 *Funding.* – The work was supported by the National Natural Science Foundation of China (grant
247 numbers 31861143050, 31772476, and 31911530077 to X.X. and grant number 82070038 to X.C.).

248 *Authors contributions.* – Conceptualization, X.C. and X.X.; methodology, H.F. and Q.Z.;
249 investigation, W.X., Z.D., G.L., and W.L.; analysis, B.Z. and S.L.; writing, original draft preparation,
250 W.X. and Q.Z.; writing, review, and editing, H.F., X.C., and X.X. All authors have read and agreed to the
251 published version of the manuscript.

252

REFERENCES

- 253 1. H. Wulff, N. A. Castle and L. A. Pardo, Voltage-gated potassium channels as therapeutic targets, *Nat.*
254 *Rev. Drug Discov.* **8** (2009) 982–1001; <https://doi.org/10.1038/nrd2983>
- 255 2. M. Bachmann, W. Li, M. J. Edwards, S. A. Ahmad, S. Patel, I. Szabo and E. Gulbins, Voltage-Gated
256 Potassium Channels as Regulators of Cell Death, *Front. Cell Dev. Biol.* **8** (2020);
257 <https://doi.org/10.3389/fcell.2020.611853>
- 258 3. C. Ashton, S. K. Rhie, J. D. Carmichael and G. Zada, Role of KCNAB2 expression in modulating
259 hormone secretion in somatotroph pituitary adenoma, *J. Neurosurg.* **134**(3) (2020) 1–7;
260 <https://doi.org/10.3171/2019.12.JNS192435>
- 261 4. R. S. Herbst, D. Morgensztern and C. Boshoff, The biology and management of non-small cell lung
262 cancer, *Nature* **553** (2018) 446–454; <https://doi.org/10.1038/nature25183>
- 263 5. M. Lu and Y. Su, Immunotherapy in non-small cell lung cancer: The past, the present, and the future,
264 *Thorac. Cancer* **10**(4) (2019) 585–586; <https://doi.org/10.1111/1759-7714.13012>
- 265 6. P. Friedl and K. Wolf, Tumour-cell invasion and migration: diversity and escape mechanisms, *Nat.*
266 *Rev. Cancer* **3** (2003) 362–374; <https://doi.org/10.1038/nrc1075>
- 267 7. R. R. Langlely and I. J. Fidler, The seed and soil hypothesis revisited-The role of tumor-stroma
268 interactions in metastasis to different organs, *Int. J. Cancer* **128**(11) (2011) 2527–2535;
269 <https://doi.org/10.1002/ijc.26031>
- 270 8. L. L. Chen, N. Blumm, N. A. Christakis, A.-L. Barabási and T. S. Deisboeck, Cancer metastasis
271 networks and the prediction of progression patterns, *Br. J. Cancer* **101** (2009) 749–758;

-
- 272 <https://doi.org/10.1038/sj.bjc.6605214>
- 273 9. K. Ganesh and J. Massagué, Targeting metastatic cancer, *Nat. Med.* **27** (2021) 34–44;
- 274 <https://doi.org/10.1038/s41591-020-01195-4>
- 275 10. R. L. Siegel, K. D. Miller and A. Jemal, Cancer statistics, 2020, *CA. Cancer J. Clin.* **70**(1) (2020) 7–
- 276 30; <https://doi.org/10.3322/caac.21590>
- 277 11. Y. Zhao and A. A. Adjei, New strategies to develop new medications for lung cancer and metastasis,
- 278 *Cancer Metastasis Rev.* **34** (2015) 265–275; <https://doi.org/10.1007/s10555-015-9553-5>
- 279 12. H. H. Popper, Progression and metastasis of lung cancer, *Cancer Metastasis Rev.* **35** (2016) 75–91;
- 280 <https://doi.org/10.1007/s10555-016-9618-0>
- 281 13. S. Kakiuchi, Y. Daigo, T. Tsunoda, S. Yano, S. Sone and Y. Nakamura, Genome-wide analysis of
- 282 organ-preferential metastasis of human small cell lung cancer in mice., *Mol. Cancer Res.* **1** (2003)
- 283 485–99.; Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12754296>
- 284 14. L. Zhang, S. Bing, M. Dong, X. Lu and Y. Xiong, Targeting ion channels for the treatment of lung
- 285 cancer, *Biochim. Biophys. Acta - Rev. Cancer* **1876** (2021) 188629;
- 286 <https://doi.org/10.1016/j.bbcan.2021.188629>
- 287 15. S. Roger, M. Potier, C. Vandier, P. Besson and J.-Y. Le Guennec, Voltage-Gated Sodium Channels:
- 288 New Targets in Cancer Therapy?, *Curr. Pharm. Des.* **12** (2006) 3681–3695;
- 289 <https://doi.org/10.2174/138161206778522047>
- 290 16. S. Roger, J. Rollin, A. Barascu, P. Besson, P.-I. Raynal, S. Iochmann, M. Lei, P. Bougnoux, Y. Gruel
- 291 and J.-Y. Le Guennec, Voltage-gated sodium channels potentiate the invasive capacities of human

-
- 292 non-small-cell lung cancer cell lines, *Int. J. Biochem. Cell Biol.* **39** (2007) 774–786;
293 <https://doi.org/10.1016/j.biocel.2006.12.007>
- 294 17. L. Gillet, S. Roger, P. Besson, F. Lecaille, J. Gore, P. Bougnoux, G. Lalmanach and J.-Y. Le Guennec,
295 Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness
296 and Colony Growth of Human Cancer Cells, *J. Biol. Chem.* **284** (2009) 8680–8691;
297 <https://doi.org/10.1074/jbc.M806891200>
- 298 18. L. Brisson, V. Driffort, L. Benoist, M. Poet, L. Counillon, E. Antelmi, R. Rubino, P. Besson, F.
299 Labbal, S. Chevalier, S. J. Reshkin, J. Gore and S. Roger, NaV1.5 sodium channels allosterically
300 regulate the NHE-1 exchanger and promote breast cancer cell invadopodial activity, *J. Cell Sci.*
301 **126** (2013) 4835–42; <https://doi.org/10.1242/jcs.123901>
- 302 19. L. WC Chow, K.-S. Cheng, K.-L. Wong and Y.-M. Leung, Voltage-gated K⁺ channels promote BT-
303 474 breast cancer cell migration, *Chinese J. Cancer Res.* **30** (2018) 613–622;
304 <https://doi.org/10.21147/j.issn.1000-9604.2018.06.06>
- 305 20. H. W. Park, M. S. Song, H. J. Sim, P. D. Ryu and S. Y. Lee, The role of the voltage-gated potassium
306 channel, Kv2.1 in prostate cancer cell migration, *BMB Rep.* **54** (2021) 130–135;
307 <https://doi.org/10.5483/BMBRep.2021.54.2.210>
- 308 21. D. Aissaoui, S. Mlayah-Bellalouna, J. Jebali, Z. Abdelkafi-Koubaa, S. Souid, W. Moslah, H. Othman,
309 J. Luis, M. ElAyeb, N. Marrakchi, K. Essafi-Benkhadir and N. Srairi-Abid, Functional role of
310 Kv1.1 and Kv1.3 channels in the neoplastic progression steps of three cancer cell lines, elucidated
311 by scorpion peptides, *Int. J. Biol. Macromol.* **111** (2018) 1146–1155;
312 <https://doi.org/10.1016/j.ijbiomac.2018.01.144>


-
- 313 22. M. Spitzner, J. Ousingsawat, K. Scheidt, K. Kunzelmann and R. Schreiber, Voltage-gated K channels
314 support proliferation of colonic carcinoma cells, *FASEB J.* **21** (2007) 35–44;
315 <https://doi.org/10.1096/fj.06-6200com>
- 316 23. S. Y. Choi, H.-R. Kim, P. D. Ryu and S. Y. Lee, Regulation of voltage-gated potassium channels
317 attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-
318 H460, *BMC Pharmacol. Toxicol.* **18** (2017) 14; <https://doi.org/10.1186/s40360-017-0118-9>
- 319 24. B. J. Mans, Evolution of Vertebrate Hemostatic and Inflammatory Control Mechanisms in Blood-
320 Feeding Arthropods, *J. Innate Immun.* **3** (2011) 41–51; <https://doi.org/10.1159/000321599>
- 321 25. J. M. C. Ribeiro and B. Arcà, Chapter 2 From Sialomes to the Sialoverse, *Adv. In Insect Phys.* (pp.
322 59–118); [https://doi.org/10.1016/S0065-2806\(09\)37002-2](https://doi.org/10.1016/S0065-2806(09)37002-2)
- 323 26. A. C. P. Sousa, M. P. J. Szabó, C. J. F. Oliveira and M. J. B. Silva, Exploring the anti-tumoral effects
324 of tick saliva and derived components, *Toxicon* **102** (2015) 69–73;
325 <https://doi.org/10.1016/j.toxicon.2015.06.001>
- 326 27. B. Zhang, Z. Deng, B. Zeng, S. Yang, X. Chen, X. Xu and J. Wu, In-vitro effects of the FS50 protein
327 from salivary glands of *Xenopsylla cheopis* on voltage-gated sodium channel activity and motility
328 of MDA-MB-231 human breast cancer cells, *Anticancer. Drugs* **29** (2018) 880–889;
329 <https://doi.org/10.1097/CAD.0000000000000662>
- 330 28. Z. Deng, Q. Zeng, J. Tang, B. Zhang, J. Chai, J. F. Andersen, X. Chen and X. Xu, Anti-inflammatory
331 effects of FS48, the first potassium channel inhibitor from the salivary glands of the flea
332 *Xenopsylla cheopis*, *J. Biol. Chem.* **296** (2021) 100670; <https://doi.org/10.1016/j.jbc.2021.100670>

-
- 333 29. Q. Zeng, W. Lu, Z. Deng, B. Zhang, J. Wu, J. Chai, X. Chen and X. Xu, The toxin mimic FS48 from
334 the salivary gland of *Xenopsylla cheopis* functions as a Kv1.3 channel-blocking immunomodulator
335 of T cell activation, *J. Biol. Chem.* **298** (2022) 101497; <https://doi.org/10.1016/j.jbc.2021.101497>
- 336 30. W. Il Jeon, P. D. Ryu and S. Y. Lee, Effects of voltage-gated K⁺ channel blockers in gefitinib-
337 resistant H460 non-small cell lung cancer cells., *Anticancer Res.* **32** (2012) 5279–84.; Retrieved
338 from <http://www.ncbi.nlm.nih.gov/pubmed/23225427>
- 339 31. J. Wu, H. Zhang, X. Chen, J. Chai, Y. Hu, W. Xiong, W. Lu, M. Tian, X. Chen and X. Xu, FM-
340 CATH, A Novel Cathelicidin From *Fejervarya Multistriata*, Shows Therapeutic Potential for
341 Treatment of CLP-Induced Sepsis, *Front. Pharmacol.* **12** (2021);
342 <https://doi.org/10.3389/fphar.2021.731056>
- 343 32. M. Song, S. Park, J. Park, J. Byun, H. Jin, S. Seo, P. Ryu and S. Lee, Kv3.1 and Kv3.4, Are Involved
344 in Cancer Cell Migration and Invasion, *Int. J. Mol. Sci.* **19** (2018) 1061;
345 <https://doi.org/10.3390/ijms19041061>
- 346 33. K. Silver, A. Littlejohn, L. Thomas, E. Marsh and J. D. Lillich, Inhibition of Kv channel expression
347 by NSAIDs depolarizes membrane potential and inhibits cell migration by disrupting calpain
348 signaling, *Biochem. Pharmacol.* **98** (2015) 614–628; <https://doi.org/10.1016/j.bcp.2015.10.017>
- 349 34. W. K. K. Wu, G. R. Li, T. M. Wong, J. Y. Wang, L. Yu and C. H. Cho, Involvement of voltage-gated
350 K⁺ and Na⁺ channels in gastric epithelial cell migration, *Mol. Cell. Biochem.* **308** (2008) 219–226;
351 <https://doi.org/10.1007/s11010-007-9631-2>
- 352 35. J. N. Rao, O. Platoshyn, L. Li, X. Guo, V. A. Golovina, J. X. J. Yuan and J.-Y. Wang, Activation of
353 K⁺ channels and increased migration of differentiated intestinal epithelial cells after wounding,

-
- 354 *Am. J. Physiol. Physiol.* **282** (2002) C885–C898; <https://doi.org/10.1152/ajpcell.00361.2001>
- 355 36. S.-H. Wu, Y.-T. Hsiao, C.-L. Kuo, F.-S. Yu, S.-C. Hsu, P.-P. Wu, J.-C. Chen, T.-C. Hsia, H.-C. Liu,
356 W.-H. Hsu and J.-G. Chung, Bufalin Inhibits NCI-H460 Human Lung Cancer Cell Metastasis In
357 Vitro by Inhibiting MAPKs, MMPs, and NF- κ B Pathways, *Am. J. Chin. Med.* **43** (2015) 1247–
358 1264; <https://doi.org/10.1142/S0192415X15500718>
- 359 37. J. H. Kim, E. B. Cho, J. Lee, O. Jung, B. J. Ryu, S. H. Kim, J. Y. Cho, C. Ryou and S. Y. Lee,
360 Emetine inhibits migration and invasion of human non-small-cell lung cancer cells via regulation
361 of ERK and p38 signaling pathways, *Chem. Biol. Interact.* **242** (2015) 25–33;
362 <https://doi.org/10.1016/j.cbi.2015.08.014>
- 363 38. C. Zhang, N. B. Leighl, Y.-L. Wu and W.-Z. Zhong, Emerging therapies for non-small cell lung
364 cancer, *J. Hematol. Oncol.* **12** (2019) 45; <https://doi.org/10.1186/s13045-019-0731-8>

365

366



368

369

370 Fig. 1. Effects of FS48 on the proliferation and mobility of NCI-H460 cells. a-c) Effects of FS48 on the


371 proliferation of NCI-H460 cells. NCI-H460 cells were treated with indicated concentrations of FS48 and

372 incubated for 24, 48, and 72 h before its proliferations were assessed by MTT; d) wound healing assay;

373 e) statistical analysis for wound healing assay; f) transwell invasion assay; g) statistical analysis for

374 wound healing assay. Data are represented as mean \pm SEM ($n = 3$). *** $p < 0.001$ compared with control.

375



376

377

378 Fig. 2. Effects of FS48 on K_v currents in NCI-H460 cells. a) Representative K^+ currents recorded in NCI-


379 H460 cells before and after perfusion with $10 \mu\text{mol L}^{-1}$ FS48 or 20mmol L^{-1} TEA. Currents were evoked

380 by 100 ms voltage steps from a holding potential of -70mV to $+25 \text{mV}$; b) current-voltage relationships

381 (-70 to $+25 \text{mV}$ at 5mV intervals). Data are represented as mean \pm SEM ($n = 3$).

382

383



384


385 Fig. 3. Effects of FS48 on $K_v1.1$ and $K_v1.3$ expression. a) Expression of $K_v1.1$ and $K_v1.3$ in NCI-H460

386 cells after 24 h incubation with FS48 was analyzed with Western blot; b) quantitative analysis of Western

387 blot; c) effect of FS48 on relative $K_v1.1$ and $K_v1.3$ mRNA levels in NCI-H460 cells. Data are represented

388 as mean \pm SEM ($n = 3$). $*p < 0.05$, $**p < 0.01$, and $***p < 0.001$ compared with control.

389



390

391 Fig. 4. The expression changes of MMP-9 and TIMP-1 in NCI-H460 cells. a) Gelatinase activities for
 392 band densities of MMP-9 from HCl-H460 cells treated with FS48 for 24 h; b) quantitation of gelatinase
 393 zymogram; c) effect of FS48 on relative MMP-9 and TIMP-1 mRNA levels in NCI-H460 cells. Data are
 394 represented as mean \pm SEM ($n = 3$). *** $p < 0.001$ compared with control.

395